Table 1.

Descriptive analysis of KTRs

Malignancy Group (n = 23)Control Group (n = 82)
Dialysis duration (mo)51.7 ± 71.736.4 ± 40.3
Age at the graft (yr)52.6 ± 849.6 ± 7.3
Gender (male/female)15/851/31
Mean time of study (yr)8.5 ± 0.98.2 ± 1
Immunosuppressive treatment
    cyclosporin/tacrolimus12/1138/44
    azathioprine/mycophenolate mofetil14/927/55
    ATG/ anti-IL-2 receptor antibody/no induction8/1/1421/5/56
HLA MMs
    0 to 1 MM (%)7 (30)11 (14)
    2 to 4 MMs (%)16 (70)69 (85)
    5 to 6 MMs (%)01 (1)
CMV status
    D+R− (%)3 (13)18 (22)
    D−R− (%)7 (30)4 (5)
    R+ (%)13 (56)60 (73)
Postgraft CMV infection (%)7 (30)32 (39)
Pre- or postgraft CMV infection (%)15 (65)73 (89)
Delayed graft function (%)11 (48)47 (57)
Acute rejection3 (13)13 (16)
Acute rejection treatment (steroid/ATG)1/23/14